Sagimet CMO granted 264,759 stock options

Sagimet Biosciences reported that Chief Medical Officer Andreas Grauer received a grant of stock options covering 264,759 shares of Series A common stock.

Rhea-AI Filing Summary

Sagimet Biosciences reported that Chief Medical Officer Andreas Grauer received a grant of stock options covering 264,759 shares of Series A common stock. The options have an exercise price of $6.44 per share and expire on April 19, 2036.

According to the vesting terms, 25% of the underlying shares vest on April 20, 2027, with the remaining 75% vesting in 36 equal monthly installments, contingent on continued service. Following this grant, Grauer holds derivative rights over 264,759 shares through this option award.

Insider Trade Summary

Grant/Award: 264,759 shares

Grant/Award 1 txn

Insider Grauer Andreas

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	264,759	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 264,759 contracts (Direct)

Footnotes (1)

1. F1. 25% of the shares underlying this option shall vest and become exercisable on April 20, 2027, with the remaining 75% vesting over thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Option grant size: 264,759 shares Exercise price: $6.44 per share Expiration date: April 19, 2036 +3 more

6 metrics

Option grant size 264,759 shares Stock Option (Right to Buy) underlying Series A common stock

Exercise price $6.44 per share Conversion or exercise price of option grant

Expiration date April 19, 2036 Option expiration for 264,759-share award

Initial vesting tranche 25% of shares Vests and becomes exercisable on April 20, 2027

Remaining vesting schedule 75% over 36 months Equal monthly installments after April 20, 2027

Holdings after grant 264,759 derivative shares Total shares underlying options following transaction

Key Terms

Stock Option (Right to Buy), Series A Common Stock, exercise price, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Series A Common Stock financial

"underlying_security_title: Series A Common Stock"

Series A common stock is a specific class of a company’s ordinary shares issued during an early formal funding round, carrying the ownership rights and voting power tied to that class. For investors it signals an early-stage equity claim with potential upside if the business grows, but also greater risk and typically less liquidity than shares in mature, publicly traded firms—imagine buying a seat on a startup’s team before the company has proven itself.

exercise price financial

"conversion_or_exercise_price: 6.4400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"25% of the shares underlying this option shall vest and become exercisable"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Sagimet Biosciences (SGMT) disclose about Andreas Grauer in this Form 4?

Sagimet Biosciences reported that Chief Medical Officer Andreas Grauer received a stock option grant for 264,759 shares of Series A common stock. This award represents compensation, giving him the right to buy shares at a fixed price in the future.

How many Sagimet Biosciences (SGMT) shares are covered by Andreas Grauer’s new options?

The grant covers 264,759 shares of Sagimet Biosciences Series A common stock. These are not currently owned shares, but rights to buy shares under the option, subject to vesting and payment of the exercise price.

What is the exercise price of Andreas Grauer’s Sagimet Biosciences (SGMT) stock options?

The stock options have an exercise price of $6.44 per share. This means Grauer can buy shares at $6.44 once portions of the award vest, regardless of the market price at that time, until the options expire.

When do Andreas Grauer’s Sagimet Biosciences (SGMT) options vest?

Vesting occurs over time: 25% of the shares vest on April 20, 2027. The remaining 75% vest in 36 equal monthly installments after that date, as long as Grauer continues to provide service to the company.

What is the expiration date of the Sagimet Biosciences (SGMT) options granted to Andreas Grauer?

The options expire on April 19, 2036. After this date, any unexercised portion of the 264,759-share award will lapse, and Grauer will no longer be able to purchase shares under this specific grant.

Is Andreas Grauer’s Sagimet Biosciences (SGMT) option grant an open-market purchase or compensation award?

The filing classifies the transaction as a grant or award acquisition, not an open-market purchase. It represents compensation in the form of options, with an exercise price of $6.44 and time-based vesting conditions tied to continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 05:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grauer Andreas

(Last) (First) (Middle)

SAGIMET BIOSCIENCES INC.

155 BOVET ROAD, SUITE 303

(Street)

SAN MATEO CALIFORNIA 94402

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sagimet Biosciences Inc. [ SGMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.44	04/20/2026		A		264,759		(1)	04/19/2036	Series A Common Stock	264,759	$0	264,759	D

Explanation of Responses:

1. 25% of the shares underlying this option shall vest and become exercisable on April 20, 2027, with the remaining 75% vesting over thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Elizabeth Rozek, Attorney-in-Fact	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)